Casdin Partners Master Fund, L.P. bought LAB
March 18, 2024 · Form 4 insider transaction
Casdin Partners Master Fund, L.P. bought 32,525,821 shares of Standard BioTools Inc. at $2.75 per share, a transaction worth $89.45M. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
32,525,821
Price
$2.75
Total value
$89.45M
Role—
CompanyStandard BioTools Inc. (LAB)
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateMarch 18, 2024
Filing dateMarch 20, 2024
Shares owned after44,023,749
OwnershipIndirect
10b5-1 planNo
AmendedNo
Footnotes
The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.